Related Experiment Video
Updated: Jul 5, 2025

05:23
Visualization of SARS-CoV-2 using Immuno RNA-Fluorescence In Situ Hybridization
Published on: December 23, 2020
6.1K
Unique tRNA Fragment Upregulation with SARS-CoV-2 but Not with SARS-CoV Infection
Isabella Imirowicz1, Azeem Saifee1, Leanne Henry1
1Outreach Division, miRcore, Ann Arbor, MI 48104, USA.
International Journal of Molecular Sciences
|January 11, 2024
Summary
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection significantly alters tRNA fragments (tRFs), unlike other viruses. These tRF changes may explain the distinct neurological effects observed in SARS-CoV-2 patients.
Area of Science:
- Molecular Biology
- Virology
- Genomics
Background:
- Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causes widespread infection with long-term neurological effects.
- Understanding SARS-CoV-2 infection mechanisms is crucial for addressing its impact.
Purpose of the Study:
- To comparatively analyze changes in tRNA fragments (tRFs) during SARS-CoV and SARS-CoV-2 infections.
- To identify potential roles of tRFs in SARS-CoV-2-associated neurological symptoms.
Main Methods:
- Analysis of publicly available total and small RNA sequencing data from Calu3 cell lines.
- Comparative analysis of tRF expression profiles in SARS-CoV and SARS-CoV-2 infected cells.
- Integration of expression data with theoretical target predictions for tRFs.
Main Results:
- Extensive upregulation of multiple tRFs observed exclusively in SARS-CoV-2 infection.
- Significant downregulation of tRNA methyltransferase (TRDMT1) identified only in SARS-CoV-2 infection.
- Enrichment of neural functions, including axon guidance, among predicted tRF targets and downregulated genes in SARS-CoV-2 infection.
Conclusions:
- tRFs exhibit distinct expression patterns in SARS-CoV-2 infection compared to SARS-CoV.
- Downregulation of TRDMT1 may be an upstream event in SARS-CoV-2 infection.
- tRFs are implicated in the neurological manifestations of SARS-CoV-2 infection, potentially through targeting genes like SEMA3C.

